|
2025 Annual Meeting Recap
Investment Updates and Portfolio Progress
| | |
This year's annual meeting, held at the Ritz-Carlton, St. Louis on April 29th, marked RiverVest's 25th anniversary.
- Attendees heard from RiverVest Co-Founder and Managing Director Jay Schmelter, as well as members of the RiverVest team, about the progress, challenges, and opportunities across the Firm's investment portfolio.
- Portfolio company presenters included Keting Chu, MD, PhD, founder & CEO/chairman of Bluejay Therapeutics, and Peter McWilliams, PhD, chief business officer of Glycomine.
- Our keynote speaker was Elias Zerhouni, former director of the National Institutes for Health.
- And Tom Melzer, co-founder and managing director of RiverVest, reflected on his 25 years in life science venture capital with RiverVest.
| | Clockwise from top left: Keting Chu, Peter McWilliams, John McKearn, Tom Melzer and RiverVest team panel (Derek Rapp, Pascal Krotee, Isaac Zike, Karen Spilizewski, and Jay Schmelter). | | Elias Zerhouni in conversation with Niall O'Donnell | | The Sugar Fix: A New Approach to Treating a Rare Glycosylation Disorder | | |
RiverVest portfolio company Glycomine recently raised $115 million in a Series C financing to fund a Phase 2b clinical trial of GLM101 – a novel sugar replacement therapy for treating a congenital disorder of glycosylation (CDG) known as PMM2-CDG.
GLM101 has demonstrated safety and efficacy in an ongoing Phase 2 open-label study and received both Orphan Drug and Rare Pediatric Disease Designations. The Phase 2b trial will involve 40 to 50 patients at 10 to 14 sites across the United States and Europe, with 24 weeks of placebo-controlled dosing followed by 24 weeks of open-label treatment. Patient enrollment is expected to begin in mid-2025, with interim results anticipated in mid-2026.
We invite you to read "The Sugar Fix" to learn more about Glycomine’s promising solution for treating a life-threatening rare disease.
| | |
For up-to-the-minute portfolio company news and announcements, be sure to visit the RiverVest website and follow us on LinkedIn.
Recent announcements include:
| | | | Publishes Preclinical Data Supporting Investigational RNAi Therapy for KCNT1-Related Epilepsy – 4/8/2025 | | | | Completes Successful Phase 1 Clinical Trials of AP02, its Novel Inhaled Formulation of Nintedanib, Preparing for Phase 2 Development in Idiopathic Pulmonary Fibrosis – 4/1/2025 | | | | Announces Close of $100M Series C Financing to Advance Its Biowearable Platform for Metabolic Health – 4/22/2025 | | | | |
Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic Dysfunction – Associated Steatohepatitis (MASH) – 5/7/2025
Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug (BJT-778) as a Monotherapy Treatment for Chronic Hepatitis D – 3/26/2025
| | | | Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDG – 4/16/2025 | | | | Acquired by MaxCyte to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments – 1/30/2025 | | | | |
Presents FLEX Vessel Prep™ System FLEX FIRST AV Registry 6-Month Data and the Hamburg Vessel Prep Experience Prior to Angioplasty at Charing Cross Symposium – 4/23/2025
Strengthens Commercial Leadership and Expands Clinical Evidence to Drive FLEX Vessel Prep™ System Growth – 3/12/2025
| | | | |
Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007 – 3/20/2025
Announces Appointment of Jim Faulkner, Ph.D., as Chief Technology Officer – 2/26/2025
| | | | Announces updated Phase 2 Data for Vilastobart, a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - 5/31/2025 | | |
RiverVest Venture Partners is a leading life science venture capital firm focused on improving the lives of patients, supporting entrepreneurs, and earning the trust of investors through science, strategy, and innovation.
St. Louis - San Diego - Cleveland - Tel Aviv
| | | | |
